Nordic Nanovector - Småprat 2019 (NANO)

[Bingo123]

Hva skjer her egentlig. Blir det ikke medisin allikevel? Eller er det absolutt ingen grunn til at den har rast ned til 33 fra emisjon på 114? Ikke fundamentalt begrunnet i det hele tatt?

[Ratzeputz]

Det blir medisin!

Er bare nede for å ta sats🚀

En fin kjøpsanledning nå.

[dr.Stockman]

I ferietider tar gjerne kjøperne pause, mens de som av forskjellige grunner er nødt til å selge ikke har noe valg.

[Chrkni]

Hva skjer her egentlig. Blir det ikke medisin allikevel? Eller er det absolutt ingen grunn til at den har rast ned til 33 fra emisjon på 114? Ikke fundamentalt begrunnet i det hele tatt?

Nja, det har jo vært litt utsettelser og det har nok bidratt, kanskje konkurransebildet tynger en del også.

[Nocturne]

Det er også spekulasjoner rundt forbi at de ligger litt bak skjema. Normalt er no news, good news, men det virker ikke slik i dette tilfellet. Jeg velger likevel å la tvilen komme Nano til gode som alltid.

[mukd]

Er denne ny eller bare gått meg hus forbi?

[Bobo]

Den er ny ja.

[Mags70]

Fin melding som kom nå

Og dermed fløy kursen rett opp i 34!
Neida, elsker denne aksjen. Og kan jo ikke være negativt at ledelsen bekrefter at "
Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)"

[Savepig]

Prøver meg med en trade på denne.

Nordic Nanovector - Fundamentale forhold 2019 (NANO)

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)

Oslo, Norway, 11 July 2019

Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been
…

Vis børsmeldingen

enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan
-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma
(DLBCL) not eligible for stem cell transplantation.

The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation
study designed to assess the safety, tolerability, pharmacokinetic profile and
preliminary anti-tumour activity of a single administration of Betalutin®.
Patients were enrolled at clinical trial sites in the US and Europe. More
information on this study can be found at www.clinicaltrials.gov (NCT02658968).
Preliminary results are expected in the second half of 2019.

DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up
to 43% of all NHL cases, making it the most common form of the disease.
Approximately 40% of DLBCL patients relapse after first-line combination
treatment with rituximab and chemotherapy and only 30-40% of relapsed patients
respond with subsequent high-dose chemotherapy followed by Stem Cell
Transplantation (ref. 1 below). There are currently very few therapeutic options
for patients not eligible for SCT, which makes relapsed DLBCL a serious unmet
medical need. The number of diagnosed cases of DLBCL in the US and Europe in
2016 was 26,500 and 17,200, respectively. These numbers are expected to reach
31,500 (US) and 19,000 (Europe) by 2024 (ref. 2 below).

Lisa Rojkjaer, Chief Medical Officer at Nordic Nanovector, said: “We are
delighted to have reached this important milestone and look forward to the
preliminary results during the second half of the year. Planning is underway for
an expansion cohort to further assess safety and efficacy in this challenging to
treat patient population. We expect more patients to be enrolled when the best
dose is selected from the first part of the study.”

References

1. L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse
   large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66-70

2. Non-Hodgkin’s Lymphoma (2015) Decision Resources

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin’s
lymphoma (NHL). NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly USD 29 billion by
2026. Nordic Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management’s current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector’s business, financial condition and results
of operations. The terms “anticipates”, “assumes”, “believes”, “can”, “could”,
“estimates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”,
“should”, “projects”, “targets”, “will”, “would” or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector’s
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector’s product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector’s potential market and
industry, Nordic Nanovector’s freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

Kilde

[jajaja]

Press releases

[InVivo]

Prøver meg med en trade på denne.

Dristig, men la gå…

[Cinvest]

Var det snakk om totalt 20-25 pasienter i DBCL som nå er ferdig rekruttert?

[Salamis]

Minimum 12, maks 24, tror jeg

[Nocturne]

Så noe interessant her. Grunn til at Nano faller… aka. “how to loose money trading stocks”.

Kl.12:39… shit! Støttenivået røk! Jeg dumper alt…

Kl. 14:33 - Shit! Melding… må kjøpe alt tilbake!

[Savepig]

Magic Bullet Biotech (magicbulletbio)

Hadde jo vært akkurat det lille hakket mer klockrent om de fikk det ut innen juni, men de 11 dagene rokker ikke ved guidingen for DLBCL fase 2 overhodet

[H.L]

Så ut som han kjøpte alt tilbake og forventet ikke reaksjonen meldingen mottok og dumpet igjen

Nye tider i biotek når en melding ikke påvirker kursen lengre

[InVivo]

men de 11 dagene rokker ikke ved guidingen for DLBCL fase 2 overhodet

Agree!

Synes det blir i overkant mye flisspikking på guiding innimellom. Tenker at i denne bransjen som må nesten akseptere at 3-6 måneders avvik i forhold til guiding er innenfor.

Nye tider i biotek når en melding ikke påvirker kursen lengre

Nå var ikke dette en melding av spesiell betydning da. Viktig i forhold til tillit ja, men ikke noe man forventer skal gi umiddelbar uttelling på kursen.

[Intendanten]

Jo, det er av betydning, men markedet mener noe annet.

[Buffert]

Merkelig opplegg. Går ikke så bra med en av «hovedkonkurrentene», Mei Pharma, om dagen heller akkurat.

[Nocturne]

Kan ikke bare være meg som gleder meg over at aksjen faller? Som langsiktig aksjonær så øyner jeg muligheten for å øke på særdeles gunstige vilkår om dette fortsetter. Skjønner at folk er biotrøtte men la oss snakkes nærmere jul. Tviler på kursen er under 40 kr da